Ionis Pharmaceuticals, Inc.
IONS
Rank in Stocks
#2587
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Share Price
$44.35
Last synced: 2026-10-19
Market Cap
$7.37B
Change (1 day)
3.28%
Change (1 year)
-39.70%
Country
US
Trade Ionis Pharmaceuticals, Inc. (IONS)
Category
Healthcare
P/B ratio for Ionis Pharmaceuticals, Inc. (IONS)
P/B ratio as of October 2026 TTM: 16.06
According to Ionis Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 16.06. At the end of 2023 the company had a P/B ratio of 18.71.
P/B ratio history for Ionis Pharmaceuticals, Inc. from 2000 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 16.06 | 80.89% |
| 2024 | 8.88 | -52.51% |
| 2023 | 18.71 | 100.05% |
| 2022 | 9.35 | 68.18% |
| 2021 | 5.56 | -47.64% |
| 2020 | 10.62 | 84.73% |
| 2019 | 5.75 | -15.77% |
| 2018 | 6.83 | -69.25% |
| 2017 | 22.20 | -61.75% |
| 2016 | 58.03 | 57.72% |
| 2015 | 36.79 | 30.53% |
| 2014 | 28.19 | 142.28% |
| 2013 | 11.63 | 102.51% |
| 2012 | 5.75 | 37.08% |
| 2011 | 4.19 | 2.15% |
| 2010 | 4.10 | 9.81% |
| 2009 | 3.74 | -81.31% |
| 2008 | 19.99 | -98.68% |
| 2007 | 1.51K | 12,449.89% |
| 2006 | 12.05 | -90.25% |
| 2005 | 123.63 | -2,768.54% |
| 2004 | -4.63 | -186.33% |
| 2003 | 5.37 | 132.40% |
| 2002 | 2.31 | -47.37% |
| 2001 | 4.39 | -25.98% |
| 2000 | 5.93 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -61.08% |
US
|
|
| 13.2547 | -17.48% |
US
|
|
| 4.208 | -73.80% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -61.51% |
NL
|
